IRCTC Stock Price and Chart NSE:IRCTC TradingView India

IRhythm Technologies, Inc. offers innovative solutions in the field of digital healthcare with its Zio ambulatory cardiac monitoring technology. Its Zio system, which combines a portable biosensor and cloud-based software, enables clinicians to efficiently and quickly diagnose arrhythmias, which can lead to more timely and effective care for patients. I believe that further expansion and market penetration by targeting the large existing ambulatory cardiac monitoring market in the United States will bring revenue growth. Sufficient marketing efforts as well as enhancement of the current portfolio of products will likely bring revenue growth. The company believes that the current market penetration is only close to 25%. 10 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for iRhythm Technologies in the last twelve months.

IRhythm Technologies, Inc. offers innovative solutions in the field of digital healthcare. IRhythm Technologies witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn’t suggest further strength…

Stock Money Flow

As of December 31, 2022, iRhythm reported cash and cash equivalents of $78 million, with short-term investments of $134 million and accounts receivable of $49 million. Also, with inventory worth $15 million and prepaid expenses and other current assets of $10 million, total current assets were equal to $288 million. The total amount of current assets is around 2.9x the total amount of current liabilities, so I do not believe that we have a liquidity issue here. I believe that having a careful look at the expectations from other investment analysts will help the investors who may not believe in the future of the products.

Investors will likely pay special attention to the fact that iRhythm uses FDA-cleared artificial intelligence. I believe that investors will likely pay special attention to the fact that iRhythm uses FDA-cleared artificial intelligence. Nature Medicine in 2019 published information about the results. Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.

Besides, if we sum cash of $78 million, and subtract noncurrent debt of $34 million, the company value would stand at $4.826 billion. Finally, the fair price would stand at close to $158 per share. In my view, a significant amount of cash in hand means management likely does not have to talk to financial institutions or providers to finance the operations.

Analyst Ratings

My numbers are a bit more conservative than what other investment analysts are expecting. I included 2023 net loss of -$94 million, depreciation and amortization close to $16 million, and stock-based compensation of $67 million. Besides, changes in accounts receivable of -$76 million and changes in inventory of -$8 million resulted in a net cash used in operating activities of -$1 million. If we also assume purchases of property and equipment of -$41 million, 2023 FCF would be close to -$41 million. Money Flow Uptick/Downtick RatioMoney flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an “uptick” in price and the value of trades made on a “downtick” in price.

Restricted a evaluation of methods for danger management in typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company’s dividend expressed as a percentage of its current stock price. The Company has developed a portfolio of ambulatory cardiac monitoring services on a platform, called the Zio service. Zio service consists of wearable patch-based biosensors, Zio XT and Zio AT monitors, which records and stores ECG data from every patient… IRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram monitoring products for patients at risk for arrhythmias in the United States.

• Most insurers will then base their reimbursement on the changes.
• Reimbursement of tenant improvements was assumed to be zero from 2023 to 2033.
• If we also assume purchases of property and equipment of -$41 million, 2023 FCF would be close to -$41 million.
• 20 employees have rated iRhythm Technologies Chief Executive Officer Kevin M. King on Glassdoor.com.
• The Company has developed a portfolio of ambulatory cardiac monitoring services on a platform, called the Zio service.

Average price gain of 7.64% within 30 days of this signal in last 5 years. One share of IRTC stock can currently be purchased for approximately $134.90. Sign-up to receive the latest news and ratings for iRhythm Technologies and its competitors with MarketBeat’s FREE daily newsletter. The P/E ratio of iRhythm Technologies is -34.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. 98.96% of the stock of iRhythm Technologies is held by institutions.

Based on an average daily trading volume, of 334,300 shares, the days-to-cover ratio is presently 6.8 days. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies. My figures for 2033 include net income of $211 million, depreciation and amortization close to $49 million, and stock-based compensation close to $147 million. If we also include capex of -$120 million, the FCF would be close to $364 million.

IRhythm Technologies started at buy with $185 stock price target at Truist

https://1investing.in/ has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. According to analysts’ consensus price target of $152.10, iRhythm Technologies has a forecasted upside of 14.1% from its current price of $133.33. The company’s average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings. IRhythm reported accounts payable worth $7 million, accrued liabilities of $65 million, and deferred revenue of $3 million. Finally, long term debt stands at $34 million, with total liabilities of $208 million.

As the world marches towards an automated future, the best robotics stocks have emerged as a force to be reckoned with. These stocks have effectively captured the attention of forward-thinking investo… Upgrade to MarketBeat All Access to add more stocks to your watchlist.

It is also worth noting that expectations about future FCF growth from management, investment advisors, or even my DCF model could be wrong. If the target market is overestimated, I believe that future FCF would be lower than expected, which would imply a lower implied stock price. The ability to innovate and expand internationally as well as the need to attract and retain senior management and key personnel are also significant risks. In my view, iRhythm will need a significant amount of cash for issuing new products in existing or related markets. If investors decide not to give further cash to iRhythm, I believe that FCF expectations would most likely decline.

iRhythm Technologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

High institutional ownership can be a signal of strong market trust in this company. In the past three months, iRhythm Technologies insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,831,058.00 in company stock. MarketBeat has tracked 4 news articles for iRhythm Technologies this week, compared to 3 articles on an average week. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes.

Data may be intentionally delayed pursuant to supplier requirements. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. I/we have a beneficial long position in the shares of IRTC either through stock ownership, options, or other derivatives.

I also believe that capital expenditures would likely increase as will the CFO. My numbers are pretty much aligned with previous figures for accounts receivable, accounts payable, and inventories. I am really not thinking out of the box because I want realistic figures. The company is also seeking international expansion opportunities in European countries, Japan, and the UK. In particular, in 2023, the company expects to develop new initiatives in Europe, which may bring news to the market, and accelerate the demand for the stock. Bloomberg Markets The Close Romaine Bostick breaks down the day’s top stories and trading action leading into the close.

Raised $76 million in an initial public offering on Thursday, October 20th 2016. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. 20 employees have rated iRhythm Technologies Chief Executive Officer Kevin M. King on Glassdoor.com. Kevin M. King has an approval rating of 91% among the company’s employees. This puts Kevin M. King in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

• Besides, changes in accounts receivable of -$76 million and changes in inventory of -$8 million resulted in a net cash used in operating activities of -$1 million.
• The asset/liability ratio is equal to more than 2x, so I believe that the balance sheet has a stable position.
• The company has been successful in focusing on integrated delivery networks, and is exploring opportunities in the UK, Japan, Switzerland, the Netherlands, and Spain.
• Based on an average daily trading volume, of 334,300 shares, the days-to-cover ratio is presently 6.8 days.
• This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.

Market expectations include 2025 net sales of $680 million, net sales growth close to 19%, 2025 EBITDA of $68.5 million, an EBITDA margin of 10%, and 2025 net income close to -$38.1 million. Intraday Data provided by FACTSET and subject to terms of use. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

IRTC Company Calendar

IRhythm Technologies, Inc. is a digital healthcare company, which engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA. Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. To calculate, start with total shares outstanding and subtract the number of restricted shares.

As the name implies, momentum trading relies on reacting to the current movement o… IRhythm Technologies delivered earnings and revenue surprises of 23.17% and 2.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock… Within Tourism & Hospitality sector IRCTC, Thomas Cook Ltd. and Wonderla Holidays Ltd. are usually compared together by investors for analysis. Within Tourism & Hospitality sector, it’s market cap rank is 1.

The company is exposed to various risks and uncertainties, including those related to regulation and reimbursement by Medicare and other commercial payers. If doctors, regulators, and insurance companies decide that the devices are too expensive or not necessary, I believe that revenue expectations would decline. In particular, we do not know yet how European or Japanese hospitals and the social security systems will feel about the innovations offered by iRhythm. The state-owned company entered the primary markets by listing in October 2019 and enjoys a strong monopoly.

To see all exchange delays and terms of use please see Barchart’s disclaimer. The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. IRhythm Technologies has a short interest ratio (“days to cover”) of 6.8.

The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. The net income growth, CFO growth, and FCF growth that I assumed are aligned with the expected growth of the global ambulatory cardiac monitoring devices market, which appears to be close to 10%. My numbers are a bit more significant than that of the market because iRhythm is a new entrant. Cash offers is dedicated to delivering an amazing shopping experience to its valued consumers in every transaction. They ensure that their customers are pleased with the transaction by providing pricing that are competitive and great service. Visit https://www.cashoffers.com/maine/.

The assumptions I made in my DCF model included deleting certain items from the cash flow statement because they do not seem like activities related to the business model. Reimbursement of tenant improvements was assumed to be zero from 2023 to 2033. I also assumed that impairment changes and changes due to other assets would be close to zero. My cash flow model includes gradual increases in FCF driven by increases in net income accompanied by increases in depreciation, increases in accounts payable, and increases in deferred revenue.